DK1886704T3 - Absorberingsmiddel og søjle til ekstrakorporal cirkulation - Google Patents
Absorberingsmiddel og søjle til ekstrakorporal cirkulation Download PDFInfo
- Publication number
- DK1886704T3 DK1886704T3 DK06730892.4T DK06730892T DK1886704T3 DK 1886704 T3 DK1886704 T3 DK 1886704T3 DK 06730892 T DK06730892 T DK 06730892T DK 1886704 T3 DK1886704 T3 DK 1886704T3
- Authority
- DK
- Denmark
- Prior art keywords
- absorbent
- blood
- column
- fiber
- granulocytes
- Prior art date
Links
- 239000002250 absorbent Substances 0.000 title claims description 259
- 230000002745 absorbent Effects 0.000 title claims description 259
- 230000004087 circulation Effects 0.000 title claims description 69
- 239000000835 fiber Substances 0.000 claims description 169
- 210000004369 blood Anatomy 0.000 claims description 157
- 239000008280 blood Substances 0.000 claims description 157
- 238000010521 absorption reaction Methods 0.000 claims description 106
- 239000004745 nonwoven fabric Substances 0.000 claims description 105
- 210000003714 granulocyte Anatomy 0.000 claims description 81
- 102000004127 Cytokines Human genes 0.000 claims description 57
- 108090000695 Cytokines Proteins 0.000 claims description 57
- 239000002158 endotoxin Substances 0.000 claims description 55
- 210000004698 lymphocyte Anatomy 0.000 claims description 55
- 210000001616 monocyte Anatomy 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 54
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 42
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 41
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 41
- 102000004889 Interleukin-6 Human genes 0.000 claims description 39
- 108090001005 Interleukin-6 Proteins 0.000 claims description 39
- 229940100601 interleukin-6 Drugs 0.000 claims description 39
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 38
- 108010002352 Interleukin-1 Proteins 0.000 claims description 34
- 102000000589 Interleukin-1 Human genes 0.000 claims description 34
- 210000000601 blood cell Anatomy 0.000 claims description 31
- 150000001412 amines Chemical group 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 125000003277 amino group Chemical group 0.000 claims description 24
- 125000000524 functional group Chemical group 0.000 claims description 20
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 20
- 239000012510 hollow fiber Substances 0.000 claims description 19
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 17
- 108010014723 immunosuppressive acidic protein Proteins 0.000 claims description 14
- 230000003100 immobilizing effect Effects 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 11
- 108010071289 Factor XIII Proteins 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 11
- 239000012894 fetal calf serum Substances 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 102000003814 Interleukin-10 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 229940076144 interleukin-10 Drugs 0.000 claims description 10
- 102000004890 Interleukin-8 Human genes 0.000 claims description 8
- 108090001007 Interleukin-8 Proteins 0.000 claims description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
- 229940096397 interleukin-8 Drugs 0.000 claims description 8
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 8
- 229940105784 coagulation factor xiii Drugs 0.000 claims description 6
- UQKAOOAFEFCDGT-UHFFFAOYSA-N n,n-dimethyloctan-1-amine Chemical compound CCCCCCCCN(C)C UQKAOOAFEFCDGT-UHFFFAOYSA-N 0.000 claims description 4
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 239000006096 absorbing agent Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000000306 component Substances 0.000 description 63
- -1 polypropylene Polymers 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 238000011275 oncology therapy Methods 0.000 description 39
- 210000000265 leukocyte Anatomy 0.000 description 35
- 238000000034 method Methods 0.000 description 35
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 30
- 238000012545 processing Methods 0.000 description 29
- 239000004743 Polypropylene Substances 0.000 description 27
- 229920001155 polypropylene Polymers 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 241000282414 Homo sapiens Species 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 24
- 229920000642 polymer Polymers 0.000 description 23
- 239000002131 composite material Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 19
- 229920000728 polyester Polymers 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000004793 Polystyrene Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 229920002223 polystyrene Polymers 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 241000700159 Rattus Species 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 230000007423 decrease Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229920001577 copolymer Polymers 0.000 description 12
- 239000011162 core material Substances 0.000 description 12
- MMINFSMURORWKH-UHFFFAOYSA-N 3,6-dioxabicyclo[6.2.2]dodeca-1(10),8,11-triene-2,7-dione Chemical group O=C1OCCOC(=O)C2=CC=C1C=C2 MMINFSMURORWKH-UHFFFAOYSA-N 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 238000007334 copolymerization reaction Methods 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 229920000669 heparin Polymers 0.000 description 10
- 230000001506 immunosuppresive effect Effects 0.000 description 10
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 10
- 229920002492 poly(sulfone) Polymers 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 102000008070 Interferon-gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229960003130 interferon gamma Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229920000139 polyethylene terephthalate Polymers 0.000 description 7
- 239000005020 polyethylene terephthalate Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 108010069514 Cyclic Peptides Proteins 0.000 description 6
- 102000001189 Cyclic Peptides Human genes 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 239000004952 Polyamide Substances 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 230000003308 immunostimulating effect Effects 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 229920002647 polyamide Polymers 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000004697 Polyetherimide Substances 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000008358 core component Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical group CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 229920001601 polyetherimide Polymers 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000009987 spinning Methods 0.000 description 5
- 125000001302 tertiary amino group Chemical group 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 210000003191 femoral vein Anatomy 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000004080 punching Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- 239000002759 woven fabric Substances 0.000 description 4
- 239000004642 Polyimide Substances 0.000 description 3
- 239000004734 Polyphenylene sulfide Substances 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000005179 haloacetyl group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- QMHNQZGXPNCMCO-UHFFFAOYSA-N n,n-dimethylhexan-1-amine Chemical compound CCCCCCN(C)C QMHNQZGXPNCMCO-UHFFFAOYSA-N 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 229920000069 polyphenylene sulfide Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical group N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000014828 interferon-gamma production Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
- GSVWUPPSQAZZTF-UHFFFAOYSA-N n-ethyl-n-methylhexan-1-amine Chemical compound CCCCCCN(C)CC GSVWUPPSQAZZTF-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- JCYPECIVGRXBMO-UHFFFAOYSA-N 4-(dimethylamino)azobenzene Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=CC=C1 JCYPECIVGRXBMO-UHFFFAOYSA-N 0.000 description 1
- ZNPJKSCIHJSEQZ-UHFFFAOYSA-N 4-methoxy-n,n-dimethylbutan-1-amine Chemical compound COCCCCN(C)C ZNPJKSCIHJSEQZ-UHFFFAOYSA-N 0.000 description 1
- QCXNXRUTKSIZND-UHFFFAOYSA-N 6-(dimethylamino)hexan-1-ol Chemical compound CN(C)CCCCCCO QCXNXRUTKSIZND-UHFFFAOYSA-N 0.000 description 1
- 101710153591 Albumin B Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000716136 Rattus norvegicus Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000616771 Rattus norvegicus Magnesium transporter protein 1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- IUAYMJGZBVDSGL-XNNAEKOYSA-N gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
- 229950009774 gramicidin s Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000012761 high-performance material Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- YWFWDNVOPHGWMX-UHFFFAOYSA-N n,n-dimethyldodecan-1-amine Chemical compound CCCCCCCCCCCCN(C)C YWFWDNVOPHGWMX-UHFFFAOYSA-N 0.000 description 1
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 108010017798 polymyxin S(1) Proteins 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0093—Chemical modification
- B01D67/00931—Chemical modification by introduction of specific groups after membrane formation, e.g. by grafting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28004—Sorbent size or size distribution, e.g. particle size
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28016—Particle form
- B01J20/28021—Hollow particles, e.g. hollow spheres, microspheres or cenospheres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28023—Fibres or filaments
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28033—Membrane, sheet, cloth, pad, lamellar or mat
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28078—Pore diameter
- B01J20/28085—Pore diameter being more than 50 nm, i.e. macropores
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Manufacturing & Machinery (AREA)
- Water Supply & Treatment (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (27)
1. Absorberingsmiddel, som kan absorbere granulocytter, monocytter og cy-tokin i blod, kendetegnet ved, at absorberingsmidlet har et zetapotential på -20 mV eller mere, hvilket absorberingsmiddel omfatter en vanduopløselig bærer med en funktionel gruppe bundet dertil, og den vanduopløselige bærer har et kvaternært ammoniumsalt og/eller en ligekædet aminogruppe bundet dertil.
2. Absorberingsmiddel ifølge krav 1, hvor formen af absorberingsmidlet er en form udvalgt fra en fiber, en membran, en hul fiber og en kugle.
3. Absorberingsmiddel ifølge krav 2, hvor formen af den vanduopløselige bærer er udvalgt fra en fiber eller en hul fiber med en fiberdiameter på mere end 3 pm og en kugle med et fremspring med en diameter på mere end 3 pm på overfladen.
4. Absorberingsmiddel ifølge krav 2, hvor formen af den vanduopløselige bærer er udvalgt fra en fiber eller en hul fiber med en fiberdiameter på 4 til 8 pm og en kugle med et fremspring med en diameter på 4 til 8 pm på overfladen.
5. Absorberingsmiddel ifølge krav 2, hvor formen af den vanduopløselige bærer er udvalgt fra en fiber eller en hul fiber med en fiberdiameter på 4,5 til 8 pm og en kugle med et fremspring med en diameter på 4,5 til 8 pm på overfladen.
6. Absorberingsmiddel ifølge et af kravene 3 til 5, hvor den vanduopløselige bærer endvidere omfatter en fiber eller en hul fiber med en fiberdiameter på 10 til 50 pm.
7. Absorberingsmiddel ifølge et af kravene 1 til 6, hvor det kvarternære ammoniumsalt er en gruppe, som kan tilvejebringes ved immobilisering af mindst en gruppe udvalgt fra Ν,Ν-dimethylhexylamin, N,N-dimethyloctylamin og Ν,Ν-dimethyllaurylamin til den vanduopløselige bærer.
8. Absorberingsmiddel ifølge et af kravene 1 til 6, hvor den ligekædede ami-nogruppe kan tilvejebringes ved immobilisering af tetraethylenepentamin til den vanduopløselige bærer.
9. Absorberingsmiddel ifølge et af kravene 1 til 8, hvor en absorptionsrate for lymfocytter er 40 % eller mindre, hvilken absorptionsrate måles ved passage af blod én gang gennem en søjle, som er fyldt med absorberingsmidlet, optælling af antallet af blodcellerne før og efter passagen og beregning af raten i henhold til formlen: Absorptionsrate (%) = [ (antal af lymfocytter i blod før passage gennem søjlen) - (antal af lymfocytter i blod efter passage gennem søjlen)] / (antal af lymfocytter i blod før passage gennem søjlen) x 100.
10. Absorberingsmiddel ifølge et af kravene 1 til 9, hvor cytokinet er mindst et udvalgt fra gruppen bestående af interleukin-1 (IL-1), interleukin-6 (IL-6), in-terleukin-8 (IL-8), interleukin-10 (IL-10), TNF-α, transformerende vækstfaktorbeta (TGF-β), vaskulær endotelial vækstfaktor (VEGF) og immunsuppressivt surt protein (IAP).
11. Absorberingsmiddel ifølge et af kravene 1 til 10, hvor absorptionsraten for koaguleringsfaktor XIII er 30 % eller mindre.
12. Absorberingsmiddel ifølge et af kravene 1 til 11 med zetapotentialet på -15 mV eller mere og med en kapacitet til at absorbere 90 % eller mere lipopolysaccharid (LPS) i salin indeholdende 1 volumenprocent føtalt kalveserum (FCS).
13. Absorberingsmiddel til kræftbehandling omfattende en vanduopløselig polymer, som er absorberingsmidlet ifølge krav 1, hvor absorberingsmidlet har en kapacitet til absorbering af latent transformerende vækstfaktor-β.
14. Absorberingsmiddel til kræftbehandling ifølge krav 13, hvor en absorptionsrate for granulocytter er 35 % eller mere, og en absorptionsrate for mono-cytter er 35 % eller mere, hvilken absorptionsrate måles ved passage af blod én gang gennem en søjle, som er fyldt med absorberingsmidlet, optælling af antallet af blodcellerne før og efter passagen og beregning af raten i henhold til formlerne: Absorptionsrate for granulocytter (%) = [ (antal af granulocytter i blod før passage gennem søjlen) - (antal af granulocytter i blod efter passage gennem søjlen) ] / (antal af granulocytter i blod før passage gennem søjlen) x 100; Absorptionsrate for monocytter (%) = [ (antal af monocytter i blod før passage gennem søjlen) - (antal af monocytter i blod efter passage gennem søjlen) ] / (antal af monocytter i blod før passage gennem søjlen) x 100.
15. Absorberingsmiddel til kræftbehandling ifølge krav 13 eller 14, hvor formen af den vanduopløselige polymer, som har den hydrofile aminrest bundet dertil, er en membran, en fiber eller et granulatmateriale.
16. Absorberingsmiddel ifølge et af kravene 1 til 15, hvor absorptionsraten for granulocytter er 50 % eller mere, og absorptionsraten for monocytter er 50 % eller mere, hvilken absorptionsrate måles ved passage af blod én gang gennem en søjle, som er fyldt med absorberingsmidlet, optælling af antallet af blodcellerne før og efter passagen og beregning af raten i henhold til formlerne: Absorptionsrate for granulocytter (%) = [ (antal af granulocytter i blod før passage gennem søjlen) - (antal af granulocytter i blod efter passage gennem søjlen) ] / (antal af granulocytter i blod før passage gennem søjlen) x 100; Absorptionsrate for monocytter (%) = [ (antal af monocytter i blod før passage gennem søjlen) - (antal af monocytter i blod efter passage gennem søjlen) ] / (antal af monocytter i blod før passage gennem søjlen) x 100.
17. Absorberingsmiddel ifølge et af kravene 1 til 16 med mindst en dobbeltlagsstruktur af et net og et ikke-vævet tekstil.
18. Absorberingsmiddel ifølge krav 17, hvor nettet er et net med 10 mm2 eller flere hulrum per 100 mm2.
19. Absorberingsmiddel ifølge krav 17 eller 18, hvor en hulrumsform af nettet er en firkant.
20. Absorberingsmiddel ifølge et af kravene 17 til 19, hvor en komponent af nettet er anbragt i en retning af en vinkel 90° ± 10° mod en hovedakse eller en lilleakse af det ikke-vævede tekstil i dobbeltlagsstrukturen.
21. Absorberingsmiddel ifølge et af kravene 17 til 20, hvilket absorberingsmiddel kan absorbere et fysiologisk aktivt stof og/eller celler.
22. Absorberingsmiddel ifølge et af kravene 17 til 21, hvor nettet består af et monofilament.
23. Absorberingsmiddel ifølge et af kravene 17 til 21, hvor der i nettet er sammenføjet portioner, hvor dets komponenter krydser hinanden.
24. Absorberingsmiddel ifølge et af kravene 17 til 23, hvor en bulkdensitet er 0,02 g/cm3 eller mere.
25. Blodbehandlingssøjle omfattende en beholder og absorberingsmidlet ifølge et af kravene 1 til 24 fyldt deri.
26. Blodbehandlingssøjle omfattende en cylindrisk beholder og absorberingsmidlet ifølge et af kravene 1 til 24 fyldt deri.
27. Ekstrakorporal cirkulationssøjle til kræftbehandling omfattende absorberingsmidlet til kræftbehandling ifølge et af kravene 13 til 15.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005101466 | 2005-03-31 | ||
| JP2005111652A JP2006288571A (ja) | 2005-04-08 | 2005-04-08 | 癌治療用吸着材および体外循環カラム |
| JP2005111651 | 2005-04-08 | ||
| PCT/JP2006/306944 WO2006106972A1 (ja) | 2005-03-31 | 2006-03-31 | 吸着材および体外循環用カラム |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1886704T3 true DK1886704T3 (da) | 2017-01-16 |
Family
ID=37073522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06730892.4T DK1886704T3 (da) | 2005-03-31 | 2006-03-31 | Absorberingsmiddel og søjle til ekstrakorporal cirkulation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8584869B2 (da) |
| EP (1) | EP1886704B1 (da) |
| KR (1) | KR100972702B1 (da) |
| CN (1) | CN101151056B (da) |
| CA (1) | CA2603073C (da) |
| DK (1) | DK1886704T3 (da) |
| ES (1) | ES2608854T3 (da) |
| WO (1) | WO2006106972A1 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008026667A1 (en) * | 2006-08-31 | 2008-03-06 | Toray Industries, Inc. | Adsorption carrier containing composite fiber |
| DK3789056T3 (da) * | 2007-08-31 | 2025-06-23 | Seastar Medical Inc | Indretninger til selektiv cytoferese |
| EP2286821B1 (en) * | 2008-04-14 | 2014-04-02 | Asahi Kasei Medical Co., Ltd. | Filter material for removing aggregates and method of filtering blood preparation |
| DE102009037015A1 (de) * | 2009-08-07 | 2011-02-17 | Michael Hajek | Vorrichtung und Verfahren zur Eliminierung von bioschädlichen Stoffen aus Körperflüssigkeiten |
| JP5822836B2 (ja) * | 2009-10-08 | 2015-11-24 | 大塚製薬株式会社 | 悪性腫瘍の治療のための免疫活性化血液灌流フィルタ |
| ES2861359T3 (es) * | 2009-12-01 | 2021-10-06 | Exthera Medical Corp | Dispositivo para eliminar citoquinas de la sangre con polisacáridos inmovilizados en superficie |
| ES2909788T3 (es) | 2010-10-15 | 2022-05-10 | Seastar Medical Inc | Cartucho de citaféresis y uso del mismo |
| US9802178B2 (en) | 2010-10-27 | 2017-10-31 | Toray Industries, Inc. | Carrier for blood component adsorption and blood component adsorption column |
| TWI546122B (zh) * | 2011-02-25 | 2016-08-21 | 東麗股份有限公司 | 血液成分吸附用載體及血液成分吸附管柱 |
| WO2012119646A1 (de) * | 2011-03-08 | 2012-09-13 | Kentsch Michael | Verfahren zur verminderung des risikos der metastasenbildung bei krebserkrankungen und system zum entfernen von tumorzellen aus dem blutkreislauf |
| WO2012133399A1 (ja) | 2011-03-29 | 2012-10-04 | 国立大学法人滋賀医科大学 | 免疫抑制性細胞捕集材及び免疫抑制性細胞捕集用カラム |
| CA2844452C (en) | 2011-08-09 | 2016-01-19 | Toray Industries, Inc. | Carrier for adsorption and method for producing same |
| EP2606921A1 (fr) * | 2011-12-21 | 2013-06-26 | Infomed SA | Dispositif d'épuration du sang par circulation extracorporelle |
| EP2802367A4 (en) | 2012-01-09 | 2015-12-16 | H David Humes | CARTRIDGE AND METHOD FOR INCREASING THE HEART MUSCULAR FUNCTION |
| KR101427700B1 (ko) * | 2012-06-29 | 2014-08-07 | 주식회사 아모그린텍 | 사이토카인 흡착시트, 그 제조방법 및 이를 이용한 혈액 필터 |
| JP6834677B2 (ja) * | 2016-03-30 | 2021-02-24 | 東レ株式会社 | 吸着カラム |
| US20190076819A1 (en) * | 2016-03-30 | 2019-03-14 | Toray Industries, Inc. | Fiber material and purification column |
| EP3450596B1 (en) * | 2016-04-27 | 2024-08-21 | Toray Industries, Inc. | Porous fiber, adsorbent material, and purifying column |
| JP6589993B2 (ja) * | 2016-09-09 | 2019-10-16 | 東レ株式会社 | 血液浄化用の材料 |
| RU2642272C1 (ru) * | 2016-11-22 | 2018-01-24 | Общество с ограниченной ответственностью "Научно-производственное предприятие Биотех-М" | Плазмофильтр и способ его сборки |
| CN111065425B (zh) * | 2017-09-08 | 2022-10-14 | 东丽株式会社 | 免疫抑制性蛋白质吸附材料和吸附柱 |
| EP3679964A4 (en) * | 2017-09-08 | 2021-06-02 | Toray Industries, Inc. | IMMUNOSUPPRESSOR LEUKOCYTE ADSORPTION MATERIAL AND ADSORPTION COLUMN |
| JP7429343B2 (ja) | 2018-01-05 | 2024-02-08 | パス イーエックス,インク. | 流体からの疾患材料の捕捉および除去のためのデバイス |
| JP7195572B2 (ja) * | 2018-05-28 | 2022-12-26 | 国立大学法人滋賀医科大学 | 低免疫状態の回復機能を有する細胞捕集材及び細胞捕集用カラム |
| EP3950117A4 (en) * | 2019-03-29 | 2022-05-18 | Asahi Kasei Medical Co., Ltd. | BLOOD PURIFIER |
| EP3960287B1 (en) * | 2019-04-26 | 2026-02-18 | Toray Industries, Inc. | Adsorbing material for soluble tumor necrosis factor receptor |
| WO2021106559A1 (ja) * | 2019-11-27 | 2021-06-03 | 株式会社クラレ | 表面改質繊維、補強繊維、及びそれを用いた成形体 |
| CN111961204B (zh) * | 2020-08-19 | 2022-12-30 | 重庆安体新生物技术有限公司 | 一种聚砜衍生物及其制备方法和用途 |
| US20220125381A1 (en) * | 2020-10-23 | 2022-04-28 | Boston Scientific Scimed, Inc. | Medical devices and methods for monitoring and treatment with synthetic polymers exhibiting specific binding |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4701267B1 (en) * | 1984-03-15 | 1996-03-12 | Asahi Medical Co | Method for removing leukocytes |
| JPS60193468A (ja) | 1984-03-15 | 1985-10-01 | 旭メデイカル株式会社 | 白血球除去フイルタ− |
| ES2047851T3 (es) * | 1989-05-09 | 1994-03-01 | Pall Corp | Dispositivo y metodo para disminuir el contenido de leucocitos de la sangre completa y de componentes de la sangre. |
| JP2501500B2 (ja) | 1991-09-30 | 1996-05-29 | 積水化学工業株式会社 | 顆粒球吸着用担体及び顆粒球除去装置 |
| JP3176752B2 (ja) * | 1992-03-17 | 2001-06-18 | 旭メディカル株式会社 | 血液濾過材 |
| DE69319471T2 (de) * | 1992-03-17 | 1999-04-15 | Asahi Medical Co. Ltd., Tokio/Tokyo | Filtermedium mit begrenzter negativer Oberflächenladung für die Behandlung von Blutmaterial |
| JP3239239B2 (ja) | 1992-06-22 | 2001-12-17 | 東洋濾紙株式会社 | エンドトキシン吸着能を有するセルロ−ス系微孔膜 |
| JP3301443B2 (ja) | 1992-08-25 | 2002-07-15 | テルモ株式会社 | 白血球および血小板除去フィルター |
| CA2167872C (en) * | 1995-01-27 | 2007-04-03 | Masaru Nakatani | Adsorbent for removing interleukins and tumor necrosis factor, and process for removing the same |
| EP0958839B1 (en) * | 1996-02-06 | 2004-12-29 | BELLCO S.p.A. | Adsorptive extracorporeal removal of cytokines from patients affected with acute organ failure |
| JP3817808B2 (ja) | 1997-02-17 | 2006-09-06 | 東レ株式会社 | 液体処理用カラムおよび液体処理方法 |
| JP2000237585A (ja) | 1998-12-22 | 2000-09-05 | Toray Ind Inc | 医療用吸着材料 |
| EP1057529A4 (en) * | 1998-12-22 | 2004-08-25 | Toray Industries | MATERIALS FOR THE DISPOSAL OF BACTERIAL COMPONENTS |
| JP2002113097A (ja) | 2000-05-23 | 2002-04-16 | Toray Ind Inc | 吸着材および体外循環用カラム |
| JP2002172163A (ja) | 2000-07-26 | 2002-06-18 | Toray Ind Inc | 細胞吸着材および体外循環用カラムならびにそれらの製造方法 |
| JP2002035118A (ja) | 2000-07-26 | 2002-02-05 | Toray Ind Inc | 炎症性疾患治療用カラム |
| JP4009772B2 (ja) | 2001-10-03 | 2007-11-21 | 東レ株式会社 | トランスフォーミング・グロウス・ファクター・ベータの吸着材および体外循環用カラム |
| KR20050036848A (ko) * | 2001-10-16 | 2005-04-20 | 아사히 카세이 메디칼 가부시키가이샤 | 바이러스 및 백혈구의 선택적 제거 방법, 제거재 및 제거장치 |
| JP4182682B2 (ja) | 2002-04-25 | 2008-11-19 | 東レ株式会社 | 癌胎児性抗原吸着材および体外循環用カラム |
| JP4200689B2 (ja) | 2002-05-30 | 2008-12-24 | 東レ株式会社 | 癌治療用体外循環カラム |
| JPWO2004052270A1 (ja) | 2002-12-12 | 2006-04-06 | 旭化成株式会社 | ウイルス除去バッグ及びそれを用いたウイルス除去方法 |
| JP2004248950A (ja) | 2003-02-21 | 2004-09-09 | Toray Ind Inc | 免疫抑制物質の吸着材および体外循環用カラム |
-
2006
- 2006-03-31 CN CN2006800102916A patent/CN101151056B/zh not_active Expired - Fee Related
- 2006-03-31 CA CA2603073A patent/CA2603073C/en not_active Expired - Fee Related
- 2006-03-31 ES ES06730892.4T patent/ES2608854T3/es not_active Expired - Lifetime
- 2006-03-31 EP EP06730892.4A patent/EP1886704B1/en not_active Expired - Lifetime
- 2006-03-31 DK DK06730892.4T patent/DK1886704T3/da active
- 2006-03-31 WO PCT/JP2006/306944 patent/WO2006106972A1/ja not_active Ceased
- 2006-03-31 KR KR1020077024948A patent/KR100972702B1/ko not_active Expired - Fee Related
- 2006-03-31 US US11/887,388 patent/US8584869B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR100972702B1 (ko) | 2010-07-27 |
| EP1886704A4 (en) | 2012-10-03 |
| CA2603073A1 (en) | 2006-10-12 |
| CA2603073C (en) | 2012-12-04 |
| CN101151056B (zh) | 2012-07-04 |
| EP1886704B1 (en) | 2016-09-28 |
| WO2006106972A1 (ja) | 2006-10-12 |
| US8584869B2 (en) | 2013-11-19 |
| CN101151056A (zh) | 2008-03-26 |
| US20090275874A1 (en) | 2009-11-05 |
| EP1886704A1 (en) | 2008-02-13 |
| ES2608854T3 (es) | 2017-04-17 |
| KR20070116667A (ko) | 2007-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1886704T3 (da) | Absorberingsmiddel og søjle til ekstrakorporal cirkulation | |
| KR101398768B1 (ko) | 세포 흡착 컬럼 | |
| KR101340932B1 (ko) | 복합 섬유를 포함하는 흡착 담체 | |
| CA2814942C (en) | Carrier for blood component adsorption and blood component adsorption column | |
| AU2012293188B2 (en) | Carrier for adsorption and method for producing same | |
| JP7459449B2 (ja) | 可溶性腫瘍壊死因子受容体の吸着材料 | |
| EP3195930B1 (en) | Fiber for protein adsorption and column for protein adsorption | |
| JP5167727B2 (ja) | 複合繊維を含む吸着担体 | |
| JP4983070B2 (ja) | 吸着材および体外循環用カラム | |
| AU2012221057B2 (en) | Carrier for blood component adsorption and blood component adsorption column | |
| JP5017996B2 (ja) | 白血球およびサイトカインの吸着器 | |
| JP4997770B2 (ja) | 吸着器 | |
| JP2006288571A (ja) | 癌治療用吸着材および体外循環カラム | |
| JP4982100B2 (ja) | 吸着担体および体外循環用カラム | |
| JP2007313288A (ja) | 吸着担体および体外循環用カラム |